How to buy Alexion Pharmaceuticals (ALXN) shares in the UK

Alexion Pharmaceuticals Inc (ALXN) is a publicly traded biotechnology business based in the US. It opened the day at $183.24 after a previous close of $183.4. During the day the price has varied from a low of $182.64 to a high of $185.5. The latest price was $184.2 (25 minute delay). Alexion Pharmaceuticals is listed on the NASDAQ and employs 3,837 staff. All prices are listed in US Dollars.

Best for

0% commission

Best for

Beginner investments

Best for

Mobile app

Best for

Index funds

Fees for buying 5x Alexion Pharmaceuticals shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform	Platform fee	Min. initial deposit	Trading fee estimate
	£0	$10	£4.06 £817.03 total	Go to site Capital at risk
	£0	£250	£12.94 £825.90 total	Go to site Capital at risk
	£0	No minimum	£8.13 £821.10 total	Go to site Capital at risk
	£0	£1	£20.08 £833.05 total	Go to site Capital at risk
	£0	£0.01	£0.81 £813.78 total	Go to site Capital at risk
	£9.99 per month	No minimum	£20.18 £833.15 total	Go to site Capital at risk
	£0	£50	£4.06 £817.03 total	Go to site Capital at risk
	£36 per year	£20	£19.66 £832.63 total	Read review Capital at risk

Full comparison of share dealing platforms

Alexion Pharmaceuticals share price (NASDAQ:ALXN)

Is it a good time to buy Alexion Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.

Invest in Alexion Pharmaceuticals shares with 0% commission

• Start investing from as little as $10
• Pay no stamp duty on UK shares
• Join 25 million users who trust their investments with eToro

Other fees apply. Capital at risk

Go to site

Capital at risk

Is Alexion Pharmaceuticals under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Alexion Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 59x. In other words, Alexion Pharmaceuticals shares trade at around 59x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

PEG ratio

Alexion Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1706. A PEG ratio close to 1 can be interpreted as meaning shares offer reasonable value for the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Alexion Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

EBITDA

Alexion Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $3.3 billion (£2.9 billion).

The EBITDA is a measure of a Alexion Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alexion Pharmaceuticals.

Total ESG risk score

Alexion Pharmaceuticals's total ESG risk: 28.21

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alexion Pharmaceuticals's overall score of 28.21 (as at 01/01/2019) is pretty good – landing it in it in the 26th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Alexion Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Environmental score

Alexion Pharmaceuticals's environmental score: 8.12/100

Alexion Pharmaceuticals's environmental score of 8.12 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Alexion Pharmaceuticals's social score: 17.78/100

Alexion Pharmaceuticals's social score of 17.78 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Alexion Pharmaceuticals's governance score: 15.31/100

Alexion Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Alexion Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Alexion Pharmaceuticals's controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Alexion Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Alexion Pharmaceuticals has, for the most part, managed to keep its nose clean.

Alexion Pharmaceuticals share dividends

We're not expecting Alexion Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Share price volatility

Over the last 12 months, Alexion Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alexion Pharmaceuticals's is 1.2595. This would suggest that Alexion Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Shares similar to Alexion Pharmaceuticals

Regeneron Pharmaceuticals Inc

$745.68

+$6.14 (0.83%)

Vertex Pharmaceuticals Inc

$302.02

+$1.38 (0.46%)

Moderna Inc

$125.62

-$0.05 (-0.04%)

BioNTech SE

$137.19

-$0.38 (-0.28%)

Seagen Inc

$136.87

-$2.30 (-1.65%)

Frequently asked questions

• What percentage of Alexion Pharmaceuticals is owned by insiders or institutions?

  Currently 0.268% of Alexion Pharmaceuticals shares are held by insiders and 88.023% by institutions.

• How many people work for Alexion Pharmaceuticals?

  Latest data suggests 3,837 work at Alexion Pharmaceuticals.

• When does the fiscal year end for Alexion Pharmaceuticals?

  Alexion Pharmaceuticals's fiscal year ends in December.

• Where is Alexion Pharmaceuticals based?

  Alexion Pharmaceuticals's address is: 121 Seaport Boulevard, Boston, MA, United States, 02210

• What is Alexion Pharmaceuticals's ISIN number?

  Alexion Pharmaceuticals's international securities identification number is: US0153511094

• What is Alexion Pharmaceuticals's CUSIP number?

  Alexion Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 015351109

• What is the key financial information for Alexion Pharmaceuticals?

  Financials

  Revenue TTM	$6.3 billion
  Operating margin TTM	47.41%
  Gross profit TTM	$5.5 billion
  Return on assets TTM	10.08%
  Return on equity TTM	4.43%
  Profit margin	10.89%
  Book value	$56.21
  Market capitalisation	$40.3 billion

  TTM: trailing 12 months